Sandbox shengshi: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 131: | Line 131: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR><BR> | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸ '''''[[Ceftriaxone]] 2 g IV q12h'''''<BR><BR><BR> | ||
|} | |} | ||
{| | {| | ||
Line 145: | Line 145: | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | AND | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR> ''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR>''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>''OR''<BR>▸ '''''[[Meropenem]] 2 g IV q8h''''' | ||
|} | |} | ||
|} | |} |
Revision as of 20:20, 14 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2] Sheng Shi, M.D. [3]
Medical Therapy
Empiric Treatment
- Adjunctive Dexamethasone (0.15 mg/kg IV q6h for 2—4 days) is recommended for both children and adult patients with acute bacterial meningitis.
Community-Acquired Meningitis
|
|
†Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
Healthcare-Associated Meningitis
Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1] References |